A study of the structure-activity relationships (SAR) of 2f (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed targeting the 5-position of the oxazole. Examination of a series of substituted benzene derivatives (12)(13)(14) revealed that the optimal position for substitution was the meta-position with selected members approaching or exceeding the potency of 2f. Concurrent with these studies, the effect of substitution on the pyridine ring of 2f was also examined. A series of small, non-aromatic C5-substituents was also explored and revealed that the K i follows a well-defined correlation with the Hammett σ p constant (ρ = 3.01, R 2 = 0.91) in which electron-withdrawing substituents enhance potency leading to inhibitors with K i 's as low as 400 pM (20n). Proteomic-wide screening of the inhibitors revealed that most are exquisitely selective for FAAH over all other mammalian proteases reversing the 100-fold preference of 20a (C5 substituent = H) for the enzyme TGH.Fatty acid amides are an important new class of lipid signaling molecules that modulate a number of physiological processes. Two endogenous fatty acid amides, anandamide (1a) 1 and oleamide (1b), 2-4 have emerged as prototypical members of this class that serve as chemical messengers (Figure 1). Anandamide (1a), which was only discovered a little more than a decade ago and is the most recognizable member of the endogenous fatty acid ethanolamides, 5 binds and activates both the central type-1 (CB1) and peripheral type-2 (CB2) cannabinoid receptors. Anandamide (1a), and members of the cannabinoid family, 6 have been implicated in the modulation of nociception, 7-9 feeding, 10,11 emesis, anxiety, 12 cell proliferation, 13,14 inflammation, 15 memory 16 and neuroprotection after brain injury. 17 Thus, the cannabinoids have clinical relevance for analgesia, anxiety, epilepsy, cachexia, cancer, and Alzheimer's disease as well as other neurodegenerative diseases. 18-20
NIH-PA Author ManuscriptNIH-PA Author Manuscript
NIH-PA Author ManuscriptOleamide (1b) was found to accumulate in the cerebrospinal fluid of animals under conditions of sleep deprivation and to induce physiological sleep in a dose dependent manner where it reduced motility, shortened the sleep induction period, and lengthened the time spent in slow wave sleep 2 at the expense of wakening. 2,4 In a structurally specific manner, it was found to modulate serotonergic systems 21-23 and GABAergic transmission, 24,25 block glial gap junction cell-cell communication, 26,27 decrease body temperature and locomotor activity, 28 and exhibit the characteristic in vivo analgesic and cannabinoid behavorial effects of anandamide, 21,29 albeit without direct cannabinoid receptor activation. It has been suggested that the cannabinoid behavorial effects of oleamide (1b) may be mediated through an as yet unknown distinct pharmacological target. 24 Because oleamide (1b) may play a critical role in sleep, it may provide an exciting therapeutic potential for the development of sle...